BeyondSpring Inc - Asset Resilience Ratio
BeyondSpring Inc (BYSI) has an Asset Resilience Ratio of 18.41% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how BeyondSpring Inc's Asset Resilience Ratio has changed over time. Check BYSI capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down BeyondSpring Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is BeyondSpring Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.78 Million | 18.41% |
| Total Liquid Assets | $4.78 Million | 18.41% |
Asset Resilience Insights
- Good Liquidity Position: BeyondSpring Inc maintains a healthy 18.41% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
BeyondSpring Inc Industry Peers by Asset Resilience Ratio
Compare BeyondSpring Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for BeyondSpring Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for BeyondSpring Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 18.41% | $4.78 Million | $25.93 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $34.31 Million | -- |
| 2023-12-31 | 0.78% | $193.00K | $24.81 Million | -5.44pp |
| 2022-12-31 | 6.21% | $2.87 Million | $46.22 Million | -31.44pp |
| 2021-12-31 | 37.65% | $30.74 Million | $81.65 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $117.04 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $7.06 Million | -- |
| 2017-12-31 | 9.36% | $3.07 Million | $32.83 Million | -- |
About BeyondSpring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical t… Read more